BLEOMYCIN (BLM) is an antineoplastic agent which was discovered in 1966 (Umezawa et al., 1966) and introduced into clinical use in the United States in 1970. It has been reported to be useful in treating squamous-cell carcinoma of the head and neck, and also for treatment of lymphomas and testicular carcinoma (Blum et al., 1973; De Vita, Serpick and Carbone, 1970; Ichikawa, Nakano and Hirokawa, 1969; Ichikawa, Nakano and Krokawa, 1970; Takeuchi, 1976) . Although BLM is usually said to be cell-cycle-phase non-specific because it causes some cell killing at all phases of the cell cycle, cells in M and G2 are more sensitive to the drug, and at low doses it reversibly inhibits cell progression at the S-G2 boundary (Barranco et at., 1973; Clarkson and Humphrey, 1976; Watanabe et al., 1974) .
Since the majority of antineoplastic drugs kill actively dividing cells, they probably are not as effective in killing cells in solid tumours which are remote from the vascular supply, deficient in molecular oxygen, and unlikely to be in active cell cycle. In this case, the use of one of the new generation of electronaffinic drugs, which selectively affect hypoxic cells, could be of significant value in killing those cells which escape the action of other antineoplastic agents. A number of such drugs, particularly the nitroimidazole, misonidazole (Adams, 1973;  Stratford and Adams, 1977; Hall and Biaglow, 1977) (Ham and Puck, 1962) . (Under these conditions, routine growth curves showed that the population doubling time is about 10 h.)
For preliminary experiments to test the toxicity of BLM with aerated cells, known numbers of cells were inoculated into 60 mm Falcon plastic Petri dishes, allowed to attach overnight at 37 5°C, before BLM was added at a range of concentrations. After a 30 min exposure at 37 5°C, the drug was removed, the Petri dishes rinsed and fresh growth medium added. An 8-day incubation at 37 5°C was then allowed for colony formation.
For drug experiments under hypoxia, cells were treated in suspension in glass ampoules. To induce hypoxia, large numbers of cells were crowded into a small volume of medium so that 02 was reduced to a low level by cell metabolism and respiration. This widely used method has been described in detail elsewhere (Hall, Lehnert and Roizin-Towle, 1974) . Proof that this system produces adequate levels of hypoxia is evidenced by an oxygen enhancement ratio (OER) of 3-2 when aerated and hypoxic cells are exposed to acute doses of 60Co y rays. For the short periods of time used in these experiments, the plating efficiencies for both groups of cells remained high and relatively unaffected by the experimental conditions employed.
The essential steps for producing hypoxic cells were as follows: Cells from a number of actively growing. partially confluent, stock flasks were harvested by trypsinization, washed to remove excess trypsin, counted with a Coulter electronic counter and prepared into a suspension so that the final cell concentration in the glass ampoules would contain 2 x 106 cells/ml. At this point, BLM or misonidazole was added to the cell suspension to achieve the final drug concentration required by the plan of the experiment. In one series of experiments the effect of combining 5 mm misonidazole and 4 concentrations of BLM was studied, and in this case both drugs were added together at this stage. A series of long-necked 1 ml glass ampoules were filled from this cell suspension, flushed with pure N2 containing 5% CO2 to remove the air from the space above the cells, and then heat-sealed. The ampoules were then continuously shaken and tumbled to keep the cells in suspension, and the temperature elevated to 37 5°C for 1 h to allow the residual 02 in the medium to be consumed by cell respiration. A parallel series of ampoules was filled with cells at a concentration of 104/ ml; these were gassed with a mixture of air and 5% CO2 before being heat-sealed.
Because of the lower number of cells, these ampoules remained aerated throughout. The same drug concentrations were used with aerated as with hypoxic cells.
After the sealing of all of the ampoules and the 1 h treatment at 37-5°C, they received various temperature exposures according to the plan of the particular experiment. Control ampoules were subject to the same handling procedures and temperature changes except that no drug was present.
At the conclusion of the appropriate treatments, each ampoule was vigorously agitated on a vortex mixer, before being opened and various aliquots of the cell suspension replated into tissue culture flasks containing fresh growth medium. After an incubation period of 8 days at 37 5°C, the cells were fixed and stained, and the number of macroscopic colonies per flask counted by a projection technique. Ampoules containing cells with concentrations of BLM higher than 5 ,ug/ml were washed first with saline before resuspension in fresh media. This was deemed necessary as concentrations of BLM in the medium greater than 1 ,tg/ml retarded cell growth. (Figs. 3 and 4) . Nevertheless, at normal body temperature, hypoxic cells appear to be relatively resistant to BLM. To reduce hypoxic cell survival at 37 5°C, which is the temperature of relevance to the clinical situation, misonidazole was used in combination with BLM. Although this nitroimidazole was the fruit of an intense search for an hypoxic cell radiosensitizer (Adams, 1973; Chapman et al., 1974; Sheldon, Foster and Fowler, 1974) it has since been shown to be a cytotoxic agent as well, specifically with regard to hypoxic cells (Hall and Roizin-Towle, 1975) . When hypoxic cells treated with BLM were simultaneously treated with 5 mm misonidazole (Fig. 5) their level of survival was reduced to a surviving fraction far below that of aerated cells. This could considerably augment chances for a remission or cure when treating solid tumours containing hypoxic cells. The suggestion has been made more than once that misonidazole would be a logical drug for inclusion in a chemotherapy protocol (Stratford and Adams, 1977; Sutherland et al., 1976 The experiments performed at 42 5°C showed that the cytotoxicity of BLM is greatly enhanced at an elevated temperature. This lends further support to the previous reports by Hahn, Brown and Har-Kedar, (1 975) and Twentyman (1976) . In addition, Braun and Hahn (1975) showed that I h at 43°C resulted in a fixation of the potentially lethal damage (PLD) in cells treated with BLM. This suppression of PLD repair by hyperthermia is important in the context of combination treatments, since several studies have shown that a large amount of PLD repair occurs rapidly following treatments with BLM Hahn et al., 1973; Barranco and Humphrey, 1976) .
Future planning for tumour treatment could very probably involve a multifaceted design incorporating the most expedient use of drugs, radiation and possibly hyperthermia. Since misonidazole has proved to be effective in dealing with hypoxic cells, and has already shown encouraging results in combination with radiotherapy, its low systemic toxicity and sensitizing properties could well make it a candidate for futuire use in any one or all of these disciplines.
